Advanced Oncotherapy (LON:AVO) Issues Quarterly Earnings Results

Advanced Oncotherapy (LON:AVO) issued its quarterly earnings data on Monday. The company reported GBX (9.83) (($0.12)) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of GBX (8.90) (($0.11)) by GBX (0.93) (($0.01)), Bloomberg Earnings reports.

LON:AVO remained flat at $GBX 26 ($0.32) on Wednesday. 345,853 shares of the company’s stock were exchanged, compared to its average volume of 79,755. The firm has a market capitalization of $79.66 million and a P/E ratio of -1.86. The company has a quick ratio of 0.79, a current ratio of 2.16 and a debt-to-equity ratio of 55.71. Advanced Oncotherapy has a 1-year low of GBX 20 ($0.25) and a 1-year high of GBX 44.50 ($0.55). The stock’s 50 day moving average is GBX 26.61 and its two-hundred day moving average is GBX 32.04.

About Advanced Oncotherapy

Advanced Oncotherapy PLC, together with its subsidiaries, focuses on providing radiotherapy systems for the treatment of cancer. The company operates through two segments, Proton Therapy and Healthcare Related Properties. It is developing Linac Image Guided Hadron Technology, a proton therapy system for treating cancer.

See Also: What is a management fee?

Receive News & Ratings for Advanced Oncotherapy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advanced Oncotherapy and related companies with MarketBeat.com's FREE daily email newsletter.